• Chinese
Cover Image

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Summary

Global Markets Direct's new report, "Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018" provides key market data on the Greece In Vitro Diagnostics market. The report provides value (USD) million data for each segment and sub-segment within seven market categories - Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct's team of industry experts.

Scope

  • Market size and company share data for In Vitro Diagnostics market categories - Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing.
  • Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
  • 2011 company shares and distribution shares data for each of the twelve market categories.
  • Global corporate-level profiles of key companies operating within the Greece In Vitro Diagnostics market.
  • Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Greece In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. What is This Report About?

3. In Vitro Diagnostics In Greece

  • 3.1. In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018
  • 3.2. In Vitro Diagnostics, Greece, Company Share (2010-2011)

4. Clinical Chemistry In Greece

  • 4.1. Clinical Chemistry Overall Revenue, (2004-2018)
    • 4.1.1. Clinical Chemisty Analyzers, Revenue (2004-2018)
    • 4.1.2. Urine Analysis, Revenue (2004-2018)
  • 4.2. Clinical Chemistry Distribution Share (2010-2011)
  • 4.3. Clinical Chemistry, Greece, Company Share (2010-2011)

5. Genetic Testing In Greece

  • 5.1. Genetic Testing Overall Revenue, (2004-2018)
  • 5.2. Genetic Testing Distribution Share (2010-2011)
  • 5.3. Genetic Testing, Greece, Company Share (2010-2011)

6. Haematology In Greece

  • 6.1. Haematology Overall Revenue, (2004-2018)
    • 6.1.1. Haematology Reagents, Revenue, (2004-2018)
    • 6.1.2. Immunohaematology, Revenue (2004-2018)
    • 6.1.3. Haemostasis, Revenue (2004-2018)
    • 6.1.4. Haematology Rapid Tests, Revenue (2004-2018)
  • 6.2. Haematology Distribution Share (2010-2011)
  • 6.3. Haematology, Greece, Company Share (2010-2011)

7. Histology And Cytology In Greece

  • 7.1. Histology And Cytology Overall Revenue, (2004-2018)
  • 7.2. Histology And Cytology Distribution Share (2010-2011)
  • 7.3. Histology And Cytology, Greece, Company Share (2010-2011)

8. Immuno Chemistry In Greece

  • 8.1. Immuno Chemistry Overall Revenue, (2004-2018)
    • 8.1.1. Disease Specific Immunochemistry, Revenue (2004-2018)
    • 8.1.2. Drugs of Abuse / Toxicology, Revenue (2004-2018)
    • 8.1.3. Endocrinology Tests, Revenue (2004-2018)
    • 8.1.4. Immunochemistry Rapid Tests, Revenue (2004-2018)
    • 8.1.5. Therapeutic Drug Monitoring, Revenue (2004-2018)
    • 8.1.6. Immunochemistry Analyzers, Revenue (2004-2018)
  • 8.2. Immuno Chemistry Distribution Share (2010-2011)
  • 8.3. Immuno Chemistry, Greece, Company Share (2010-2011)

9. Infectious Immunology In Greece

  • 9.1. Infectious Immunology Overall Revenue, (2004-2018)
    • 9.1.1. Infectious Immunology Rapid Tests, Revenue (2004-2018)
  • 9.2. Infectious Immunology Distribution Share (2010-2011)
  • 9.3. Infectious Immunology, Greece, Company Share (2010-2011)

10. Microbiology Culture In Greece

  • 10.1. Microbiology Culture Overall Revenue, (2004-2018)
    • 10.1.1. Microbiology Analyzers, Revenue (2004-2018)
  • 10.2. Microbiology Culture Distribution Share (2010-2011)
  • 10.3. Microbiology Culture, Greece, Company Share (2010-2011)

11. Overview of Key Companies in Greece In Vitro Diagnostics Market

  • 11.1. F. Hoffmann-La Roche Ltd.
    • 11.1.1. Company Overview
  • 11.2. Siemens Healthcare
    • 11.2.1. Company Overview
  • 11.3. Abbott Laboratories
    • 11.3.1. Company Overview
  • 11.4. Beckman Coulter, Inc.
    • 11.4.1. Company Overview
  • 11.5. Ortho-Clinical Diagnostics Inc.
    • 11.5.1. Company Overview
  • 11.6. bioMerieux S.A.
    • 11.6.1. Company Overview
  • 11.7. Sysmex Corporation
    • 11.7.1. Company Overview
  • 11.8. Becton, Dickinson and Company
    • 11.8.1. Company Overview
  • 11.9. Bio-Rad Laboratories, Inc.
    • 11.9.1. Company Overview
  • 11.10. DiaSorin S.p.A
    • 11.10.1. Company Overview
  • 11.11. Qiagen N.V.
    • 11.11.1. Company Overview
  • 11.12. Diagnostica Stago, Inc.
    • 11.12.1. Company Overview
  • 11.13. Thermo Fisher Scientific Inc.
    • 11.13.1. Company Overview
  • 11.14. Horiba, Ltd.
    • 11.14.1. Company Overview
  • 11.15. Gen-Probe Incorporated
    • 11.15.1. Company Overview
  • 11.16. Grifols, S.A.
    • 11.16.1. Company Overview
  • 11.17. Life Technologies Corporation
    • 11.17.1. Company Overview
  • 11.18. Immucor, Inc.
    • 11.18.1. Company Overview
  • 11.19. Cellestis Limited
    • 11.19.1. Company Overview
  • 11.20. Danaher Corporation
    • 11.20.1. Company Overview
  • 11.21. Phadia AB
    • 11.21.1. Company Overview

12. Appendix

  • 12.1. Global Markets Direct Research Methodology
  • 12.2. Definitions of Markets Covered in the Report
    • 12.2.1. In Vitro Diagnostics
  • 12.3. Secondary Research
  • 12.4. Primary Research
  • 12.5. Models
  • 12.6. Forecasts
  • 12.7. Expert Panel Validation
  • 12.8. Currency Conversion
  • 12.9. Contact Us
  • 12.10. Disclaimer

List of Tables

  • Table 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018
  • Table 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Historic, 2004-2011
  • Table 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
  • Table 4: In Vitro Diagnostics, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 5: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Table 6: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Table 7: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 8: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 9: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 10: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 11: Clinical Chemistry, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 12: Clinical Chemistry, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 13: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Table 14: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Table 15: Genetic Testing, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 16: Genetic Testing, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 17: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Table 18: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Table 19: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 20: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 21: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 22: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 23: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 24: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 25: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 26: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 27: Haematology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 28: Haematology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 29: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Table 30: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Table 31: Histology And Cytology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 32: Histology And Cytology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 33: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Table 34: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Table 35: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 36: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 37: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 38: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 39: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 40: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 41: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 42: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 43: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 44: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 45: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 46: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 47: Immuno Chemistry, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 48: Immuno Chemistry, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 49: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Table 50: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Table 51: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 52: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 53: Infectious Immunology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 54: Infectious Immunology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 55: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Table 56: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Table 57: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 58: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 59: Microbiology Culture, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 60: Microbiology Culture, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011

List of Figures

  • Figure 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018
  • Figure 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Historic, 2004-2011
  • Figure 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
  • Figure 4: In Vitro Diagnostics, Greece, Company Share (%), 2011
  • Figure 5: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Figure 6: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Figure 7: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 8: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 9: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 10: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 11: Clinical Chemistry, Greece, Company Share (%), 2011
  • Figure 12: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Figure 13: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Figure 14: Genetic Testing, Greece, Company Share (%), 2011
  • Figure 15: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Figure 16: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Figure 17: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 18: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 19: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 20: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 21: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 22: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 23: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 24: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 25: Haematology, Greece, Company Share (%), 2011
  • Figure 26: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Figure 27: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Figure 28: Histology And Cytology, Greece, Company Share (%), 2011
  • Figure 29: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Figure 30: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Figure 31: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 32: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 33: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 34: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 35: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 36: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 37: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 38: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 39: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 40: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 41: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 42: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 43: Immuno Chemistry, Greece, Company Share (%), 2011
  • Figure 44: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Figure 45: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Figure 46: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 47: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 48: Infectious Immunology, Greece, Company Share (%), 2011
  • Figure 49: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
  • Figure 50: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
  • Figure 51: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 52: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 53: Microbiology Culture, Greece, Company Share (%), 2011
  • Figure 54: Global Markets Direct Methodology
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top